SOT109 for Colorectal Cancer

This trial aims to test a new cancer treatment called SOT109, which targets specific markers on cancer cells in colorectal cancer, potentially sparing healthy cells. The trial consists of two parts: the first part identifies safe dose levels, while the second part determines the best dose for effectiveness and safety. It seeks individuals with advanced colorectal cancer that cannot be surgically removed or has spread, and who have already tried standard treatments without success. Participants should have colorectal cancer that has resisted standard therapies and have no other standard treatment options available. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot receive any other cancer treatments while participating. It's best to discuss your specific medications with the trial team.

Research has shown that SOT109 was safe in early lab tests, indicating it was well-tolerated before human testing. The treatment targets CDH17, a marker present in most colorectal cancer cases, while aiming to avoid damage to healthy cells. SOT109 is currently undergoing Phase 1 and Phase 2 clinical trials, which assess its safety in humans and identify any side effects. Although detailed information from human trials is not yet available, early lab results are promising.¹²³⁴⁵

Researchers are excited about SOT109 for colorectal cancer because it offers a potentially novel approach compared to existing treatments like chemotherapy and targeted therapies. Unlike other treatments that primarily target cancer cells directly, SOT109 may work by modulating the immune system to better recognize and attack cancer cells, which is a fresh angle in treating advanced colorectal cancer. Additionally, SOT109 is administered via IV once every 21 days, potentially offering a more convenient dosing schedule and less frequent hospital visits compared to some existing therapies.

Research has shown that SOT109 holds promise for treating colorectal cancer. This treatment targets cancer cells with a marker called CDH17, present in over 90% of colorectal cancer cases. In early tests, SOT109 demonstrated strong effects against tumors and appeared safe, effectively fighting cancer cells while remaining safe for patients. The treatment aims to limit harm to healthy cells, potentially resulting in fewer side effects. These findings suggest that SOT109 could be a viable option for patients with advanced colorectal cancer. Participants in this trial will receive varying doses of SOT109 to determine the optimal dosing strategy.¹⁵⁶⁷⁸